FDA staff question value of Sanofi blood clot drug
WASHINGTON, June 18
WASHINGTON, June 18 (Reuters) - U.S. drug reviewers questioned the value of preventing blood clots with Sanofi SA's semuloparin injection for cancer patients receiving chemotherapy.
The Food and Drug Administration staff said only a small number of people in the clinical trials for semuloparin actually had issues with clotting, and most people died from other problems.
"These findings call into question the clinical value of semuloparin in the proposed clinical setting," the FDA reviewers said in documents posted online on Monday.
The FDA staff review comes ahead of an advisory panel, which will vote on whether to recommend semuloparin on Wednesday. The FDA usually follows panel recommendations, although it is not required to, and will make a final decision later.
- Australian PM says police raids follow IS linked beheading plot |
- Scots vote in independence referendum to seal the United Kingdom's fate |
- Divided, Scots prepare to vote on fate of the United Kingdom |
- Dollar hits six-year peak versus yen, ECB loan demand disappoints
- Apple to unveil new iPads, operating system on Oct. 21: report